v3 Template
A
Algernon Health Inc.
Pharmaceuticals / Biotechnology
Founded
--
Employees
--
Total Funding
$3.0M
Funding Rounds
6
Last Funding
2025-12-31
About Algernon Health Inc.
Algernon Pharmaceuticals Inc. is a clinical-stage Canadian drug development and repurposing company focused on investigating drugs and naturally occurring compounds for unmet global medical needs. Their mission is to discover new therapeutic uses for off-patent drugs with established safety profiles, using a cost-effective and capital-efficient model.
Products & Services
NP-251 (Repirinast):Originally an asthma drug, now being repurposed for chronic kidney disease after showing a 50% reduction in fibrosis in preclinical models.
AP-188 (DMT):N,N-Dimethyltryptamine, a naturally occurring compound, investigated as a potential treatment for stroke and traumatic brain injury (TBI) by inducing neuroplasticity.
NP-120 (Ifenprodil):Research program for chronic cough and idiopathic pulmonary fibrosis, acquired by Seyltx Inc. in March 2024 for USD $2M and a 20% equity position.
Specialties
Drug Repurposing
Neuroplasticity Research
Chronic Kidney Disease Treatment
Stroke and Traumatic Brain Injury Treatment
Alzheimer's Diagnostics
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: Private Placement T: - FT: Private Placement |
A: 858000 MR: - FA: CAD $858,000 FAN: 858000 |
D: 2025-12-31 FD: 2025-12-31 |
1 investors |
| 2 |
RT: Private Placement T: - FT: Private Placement |
A: 750000 MR: - FA: 750,000 FAN: 750000 |
D: 2025-12-23 FD: 2025-12-23 |
- |
| 3 |
RT: Private Placement T: - FT: Private Placement |
A: 210000 MR: - FA: CAD $210,000 FAN: 210000 |
D: 2025-11-28 FD: 2025-11-28 |
- |
| 4 |
RT: Strategic Investment T: - FT: Strategic Investment |
A: 500000 MR: - FA: USD $500,000 FAN: 500000 |
D: 2025-11-17 FD: 2025-11-17 |
1 investors |
| 5 |
RT: Private Placement T: - FT: Private Placement |
A: 177000 MR: - FA: CAD $177,000 FAN: 177000 |
D: 2025-11-14 FD: 2025-11-14 |
1 investors |
| 6 |
RT: Private Placement T: - FT: Private Placement |
A: 500000 MR: - FA: $500,000 FAN: 500000 |
D: 2025-11-06 FD: 2025-11-06 |
- |
Private Placement
Latest
2025-12-31
$858K
1 investor (Pro only)
Private Placement
2025-12-23
$750K
Private Placement
2025-11-28
$210K
Growth Metrics
+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active
Mock Up
Team & Leadership
No team data available
Team information is not yet available for this company
Recent News
Algernon Health Inc. Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Mock Up
Key Competitors
C1
Competitor Alpha
Series B · $50M raised
C2
Competitor Beta
Series C · $120M raised
C3
Competitor Gamma
Series A · $25M raised
C4
Competitor Delta
Seed · $10M raised
Mock Up
Company Details
- Website
- algernonhealth.com
- Industries
- Pharmaceuticals / Biotechnology
Technology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro